Belarus has an established clinical research base, specialist medical institutions in Minsk and Gomel, EAEU regulatory alignment, and research depth across oncology, cardiovascular, infectious disease, and radiation medicine.
Belarus is a landlocked Eastern European nation of approximately 9.4 million people, bordered by Russia to the east and northeast, Ukraine to the south, Poland to the west, and Lithuania and Latvia to the northwest. Minsk, the capital and by far the largest city (~2 million), is the unambiguous centre of the country's medical, academic, and clinical research activity — home to the three leading national research institutes, the main university hospital complex, and the headquarters of every significant research stakeholder. Regional cities — Gomel, Vitebsk, Grodno, Brest, and Mogilev — each host their own hospital networks and, in the case of Vitebsk and Grodno, their own medical universities. Belarus was a founding member of the Eurasian Economic Union (EAEU) in 2015 alongside Russia and Kazakhstan, and operates within the EAEU's unified pharmaceutical regulatory market — a framework that provides a recognized GCP standard and, for sponsors operating across the CIS, a single regulatory quality infrastructure covering a combined population exceeding 183 million people.
Clinical trials are regulated by the Ministry of Health of the Republic of Belarus and, technically, by its subordinate body the Republican Unitary Enterprise "Center for Expertise and Testing in Healthcare" (RCETH), which handles pharmaceutical dossier review and clinical trial authorization. Ethics review is conducted by the Republican Ethics Committee under the Ministry of Health, operating at a national level. Sponsors considering Belarus should engage their compliance and legal teams regarding the international sanctions environment: the EU, US, UK, and other jurisdictions have imposed targeted sanctions on Belarus — primarily targeting specific individuals, entities, and sectors — since 2020, with further measures since 2022. The impact on clinical research operations varies by sponsor jurisdiction, trial type, and site-specific structure. For sponsors from non-sanctioning jurisdictions or those with appropriate compliance clearances, the Belarusian research infrastructure remains operational and accessible. Academic, humanitarian, and patient-benefit research programs are generally less affected than commercial activities.
Belarus's population is approximately 84% ethnic Belarusian, with a substantial Russian minority (~8%), Polish (~3%), Ukrainian (~1.5%), and small Jewish, Tatar, and other communities. Ethnic and cultural homogeneity is high — both Belarusian and Russian are official languages, with Russian dominant in urban and scientific contexts — and the medical community communicates research findings primarily in Russian, with English proficiency growing among the younger generation of investigators who increasingly engage with international journals and conferences. Literacy stands at approximately 99.8%. The Belarusian academic medical tradition is rooted in the Soviet model of deep specialisation, rigorous training in clinical methodology, and vertical institute structure — characteristics that produced an investigator community with genuine clinical depth that persists today. Three dedicated medical universities (Minsk, Vitebsk, Grodno) feed a consistent pipeline of GCP-trained physicians who are actively engaged with international research networks.
Belarus's disease burden follows the post-Soviet NCD pattern with two highly distinctive features. Cardiovascular disease is the leading cause of death (~55% of mortality), with coronary artery disease, hypertension, heart failure, and stroke generating large treatment-naïve patient pools given limited prior exposure to advanced modern pharmacotherapy. Cancer presents a significant and rising burden — colorectal, lung, breast, prostate, and haematologic malignancies drive the oncology trial portfolio. Belarus also carries a notably elevated burden of alcohol-use disorder, historically one of the world's highest per-capita alcohol consumption rates — creating substantial hepatology and alcohol-related liver disease patient pools of genuine research interest. HIV infection, concentrated primarily in injecting drug users, and tuberculosis, including drug-resistant strains, add infectious disease dimension. Metabolic disease and diabetes are rising as a result of demographic and lifestyle transitions.
The Chernobyl research legacy — a genuinely unique scientific asset: The 1986 Chernobyl nuclear disaster deposited approximately 70% of its total radioactive fallout on Belarusian territory, primarily across the Gomel, Mogilev, and Brest regions. Over nearly four decades, this has created an unmatched longitudinal dataset of radiation-exposed human health outcomes: documented elevation of thyroid cancer — particularly in those who were children in 1986 — rising rates of haematological malignancies, and multiple other radiation-related conditions in a well-studied, medically monitored population. The Republican Scientific Practical Center for Radiation Medicine and Human Ecology in Gomel is the world's most experienced institution in this specific field, with decades of clinical protocols, patient registries, and specialist investigator expertise in radiation health effects that no other country can replicate. For sponsors in thyroid oncology, haematology, and radiation medicine, Belarus offers a patient population and institutional research depth that is genuinely irreplaceable.
Belarus brings a combination of genuine research strengths that are rare in the CIS: a world-class national cancer centre whose oncology capabilities rival leading Western European academic institutions, a Chernobyl radiation medicine heritage that has produced the most specialised radiation health investigator community on Earth, three medical universities sustaining a trained pipeline, and per-patient economics that sit well below any Western European peer market. Sponsors who can engage under their applicable compliance frameworks will find a research-ready ecosystem anchored by decades of rigorous academic medical tradition.
EAEU Common Pharmaceutical Market membership; RCETH technical review and Republican Ethics Committee oversight; EAEU GCP standard closely aligned with ICH-GCP; regulatory data recognized across EAEU member states; sponsors must assess their applicable compliance requirements regarding international sanctions before engagement — scope varies by sponsor jurisdiction and activity type.
Per-patient and site operational costs significantly below any Western European comparator and competitive within the CIS; investigator fees and site overhead well below Polish, Baltic, or Romanian levels; strong cost-to-quality ratio given the depth of academic investigator training; lower site administration burden given Belarus's centralized national research institute structure.
Large cardiovascular treatment-naïve patient pools from a high-mortality-burden population; deep oncology cohorts at the N.N. Alexandrov Cancer Centre with the most comprehensive Belarusian cancer registry; globally unique Chernobyl-exposed thyroid cancer and haematology patient populations at Gomel; alcohol-related liver disease pools; elevated HIV and TB patient base for infectious disease programs.
N.N. Alexandrov National Cancer Centre — arguably the CIS's most capable dedicated oncology research institution; Republican Scientific Practical Centres for Cardiology, Neurology, and Radiation Medicine; three medical universities sustaining the investigator pipeline; Minsk's centralized research hub structure enables efficient multi-specialist multi-site designs within a single city; international CRO networks with CIS regional coverage.
Cardiovascular disease and oncology anchor Belarus's trial portfolio — the former driven by a population cardiovascular mortality rate that creates exceptional enrollment depth for Phase III outcomes studies; the latter by the N.N. Alexandrov Cancer Centre, whose capabilities in solid tumour surgery, radiotherapy, chemotherapy, and immuno-oncology are among the most comprehensive in Eastern Europe. The radiation medicine niche — thyroid cancer and haematological malignancies with documented Chernobyl aetiology — is Belarus's most globally differentiated research asset, with a depth of specialist investigator expertise at the Gomel Centre that no competing site anywhere in the world can match for this specific patient population. Alcohol-use disorder and alcohol-related liver disease occupy a distinctive hepatology niche. Infectious disease — HIV and tuberculosis, including MDR-TB — adds a significant third pillar. Neurology, metabolic disease, respiratory medicine, and psychiatry round out a broad and academically grounded portfolio.
Minsk dominates Belarus's clinical research landscape — the capital hosts all three national Republican Scientific Practical Centres (Cardiology, Neurology, and the main oncology complex), the BSMU clinical hospital network, and the country's largest general hospital facilities. Gomel is the essential second node, home to the world-leading Radiation Medicine Center that serves as the primary gateway to Belarus's unique Chernobyl-legacy patient populations. Vitebsk and Grodno anchor the regional network through their medical university-affiliated hospital complexes, offering geographic enrollment breadth for multi-site Belarusian trial designs.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | N.N. Alexandrov National Cancer Centre of Belarus | Minsk | Belarus's flagship national oncology institution and one of the CIS's most capable dedicated cancer research centres; Phase I–IV across solid tumours, haematologic malignancies, and radiotherapy-combined indications; houses the Belarusian national cancer registry; active in European and CIS oncology research networks; the primary portal for international oncology sponsors entering the Belarusian market, with investigator depth comparable to leading Western European academic cancer centres. |
| 02 | Republican Scientific Practical Centre "Cardiology" | Minsk | Belarus's dedicated national cardiology research and treatment centre; Phase II–IV cardiovascular outcome trials, heart failure, hypertension, arrhythmia, and interventional cardiology studies; modern catheterisation laboratory and cardiac imaging infrastructure; large treatment-naïve patient catchment reflecting Belarus's very high cardiovascular mortality burden; the country's deepest cardiovascular investigator team and the primary site for Phase III cardiovascular outcome programs. |
| 03 | 2nd Minsk City Clinical Hospital (BSMU Main Clinical Affiliate) | Minsk | The primary clinical teaching base of the Belarusian State Medical University (BSMU), the country's oldest and most prestigious medical institution; Phase II–IV across internal medicine, cardiology, oncology, neurology, and endocrinology; the largest BSMU affiliate hospital and the anchor site for the national investigator pipeline; established relationships with international CROs and a broad commercial Phase II–IV portfolio spanning multiple therapeutic areas. |
| 04 | Republican Scientific Practical Centre for Neurology and Neurosurgery | Minsk | Belarus's national specialist centre for neurology and neurosurgery; Phase II–IV trials in stroke, multiple sclerosis, Parkinson's disease, epilepsy, dementia, and neurosurgical indications; BSMU affiliate; large patient catchment as the national tertiary neurology referral centre; active European neurology network participation; key site for sponsors targeting CNS disease in a population with substantial neurological disease burden and limited prior trial exposure. |
| 05 | 9th Minsk City Clinical Hospital | Minsk | A major BSMU teaching hospital and one of Minsk's most research-active general hospital complexes; Phase II–IV across oncology, haematology, rheumatology, and internal medicine; active commercial sponsor portfolio complementing the national research centre network; significant patient throughput from the Minsk metropolitan area; established investigator community with international research experience and active publication records in major clinical journals. |
| 06 | Republican Clinical Medical Centre | Minsk | Belarus's foremost state clinical hospital, serving as the national referral centre for complex and high-acuity cases; Phase II–IV across cardiology, oncology, surgery, and internal medicine; modern infrastructure and highly experienced senior investigator team; the highest-acuity patient catchment in the country, with complex cases referred from all regional centres creating a distinctive patient profile for sponsors targeting refractory and advanced-stage indications. |
| 07 | Republican Centre of Pulmonology and Phthisiology | Minsk | Belarus's national specialist centre for tuberculosis, respiratory disease, and pulmonology; Phase II–IV in pulmonary TB, multidrug-resistant TB (MDR-TB), COPD, asthma, and interstitial lung disease; a well-characterised TB patient cohort including MDR strains of relevance to anti-infective and antimicrobial drug development pipelines; specialist investigator team with experience in WHO-sponsored and international anti-TB trial programs. |
| 08 | Republican Scientific Practical Center for Radiation Medicine and Human Ecology | Gomel | The world's most specialised institution for studying long-term radiation health effects in civilian populations, established in direct response to the 1986 Chernobyl disaster; Phase II–IV in thyroid oncology, haematological malignancies, radiation-related carcinogenesis, and radiation medicine; decades of longitudinal patient registry data on Chernobyl-exposed populations; an irreplaceable research resource for sponsors in thyroid cancer, leukaemia, and radiation biology — with no comparable competitor site anywhere on Earth. |
| 09 | Gomel Regional Clinical Hospital | Gomel | Southern Belarus's primary regional academic hospital and the main clinical research node in the Gomel Oblast — the region most heavily affected by Chernobyl fallout; Phase II–III across cardiovascular, oncology, endocrinology, and internal medicine; complements the Radiation Medicine Center for sponsors seeking to combine general Gomel population enrollment with specialist radiation medicine sub-studies in a single southern Belarus site visit. |
| 10 | Vitebsk Regional Clinical Hospital | Vitebsk | Northern Belarus's primary regional academic hospital and the main clinical base of Vitebsk State Medical University (VSMU); Phase II–III across cardiovascular, oncology, and internal medicine; VSMU affiliate; provides northern Belarusian patient population access for sponsors seeking multi-site geographic breadth in trial designs; growing research portfolio with BSMU investigator partnership programs. |
| 11 | Grodno Regional Clinical Hospital | Grodno | Western Belarus's primary regional academic hospital and the main clinical base of Grodno State Medical University (GrSMU); Phase II–III in cardiovascular, oncology, and internal medicine; GrSMU affiliate; geographically positioned adjacent to the Polish border, providing access to western Belarusian patient populations and offering a natural complement to eastern and central Belarusian site networks in multi-site study designs. |
| 12 | Mogilev Regional Clinical Hospital | Mogilev | Eastern Belarus's primary regional hospital serving the Mogilev Oblast — a region with documented Chernobyl fallout exposure in its northern districts; Phase II–III in cardiovascular, oncology, and internal medicine; provides central-eastern Belarusian patient coverage for multi-site designs; increasingly active research portfolio as investigator training programs from BSMU extend into regional hospital networks across the country. |
Belarus's flagship national oncology institution and one of the CIS's most capable dedicated cancer research centres; Phase I–IV across solid tumours, haematologic malignancies, and radiotherapy-combined indications; houses the Belarusian national cancer registry; active in European and CIS oncology research networks; the primary portal for international oncology sponsors entering the Belarusian market, with investigator depth comparable to leading Western European academic cancer centres.
Belarus's dedicated national cardiology research and treatment centre; Phase II–IV cardiovascular outcome trials, heart failure, hypertension, arrhythmia, and interventional cardiology studies; modern catheterisation laboratory and cardiac imaging infrastructure; large treatment-naïve patient catchment reflecting Belarus's very high cardiovascular mortality burden; the country's deepest cardiovascular investigator team and the primary site for Phase III cardiovascular outcome programs.
The primary clinical teaching base of the Belarusian State Medical University (BSMU), the country's oldest and most prestigious medical institution; Phase II–IV across internal medicine, cardiology, oncology, neurology, and endocrinology; the largest BSMU affiliate hospital and the anchor site for the national investigator pipeline; established relationships with international CROs and a broad commercial Phase II–IV portfolio spanning multiple therapeutic areas.
Belarus's national specialist centre for neurology and neurosurgery; Phase II–IV trials in stroke, multiple sclerosis, Parkinson's disease, epilepsy, dementia, and neurosurgical indications; BSMU affiliate; large patient catchment as the national tertiary neurology referral centre; active European neurology network participation; key site for sponsors targeting CNS disease in a population with substantial neurological disease burden and limited prior trial exposure.
A major BSMU teaching hospital and one of Minsk's most research-active general hospital complexes; Phase II–IV across oncology, haematology, rheumatology, and internal medicine; active commercial sponsor portfolio complementing the national research centre network; significant patient throughput from the Minsk metropolitan area; established investigator community with international research experience and active publication records in major clinical journals.
Belarus's foremost state clinical hospital, serving as the national referral centre for complex and high-acuity cases; Phase II–IV across cardiology, oncology, surgery, and internal medicine; modern infrastructure and highly experienced senior investigator team; the highest-acuity patient catchment in the country, with complex cases referred from all regional centres creating a distinctive patient profile for sponsors targeting refractory and advanced-stage indications.
Belarus's national specialist centre for tuberculosis, respiratory disease, and pulmonology; Phase II–IV in pulmonary TB, multidrug-resistant TB (MDR-TB), COPD, asthma, and interstitial lung disease; a well-characterised TB patient cohort including MDR strains of relevance to anti-infective and antimicrobial drug development pipelines; specialist investigator team with experience in WHO-sponsored and international anti-TB trial programs.
The world's most specialised institution for studying long-term radiation health effects in civilian populations, established in direct response to the 1986 Chernobyl disaster; Phase II–IV in thyroid oncology, haematological malignancies, radiation-related carcinogenesis, and radiation medicine; decades of longitudinal patient registry data on Chernobyl-exposed populations; an irreplaceable research resource for sponsors in thyroid cancer, leukaemia, and radiation biology — with no comparable competitor site anywhere on Earth.
Southern Belarus's primary regional academic hospital and the main clinical research node in the Gomel Oblast — the region most heavily affected by Chernobyl fallout; Phase II–III across cardiovascular, oncology, endocrinology, and internal medicine; complements the Radiation Medicine Center for sponsors seeking to combine general Gomel population enrollment with specialist radiation medicine sub-studies in a single southern Belarus site visit.
Northern Belarus's primary regional academic hospital and the main clinical base of Vitebsk State Medical University (VSMU); Phase II–III across cardiovascular, oncology, and internal medicine; VSMU affiliate; provides northern Belarusian patient population access for sponsors seeking multi-site geographic breadth in trial designs; growing research portfolio with BSMU investigator partnership programs.
Western Belarus's primary regional academic hospital and the main clinical base of Grodno State Medical University (GrSMU); Phase II–III in cardiovascular, oncology, and internal medicine; GrSMU affiliate; geographically positioned adjacent to the Polish border, providing access to western Belarusian patient populations and offering a natural complement to eastern and central Belarusian site networks in multi-site study designs.
Eastern Belarus's primary regional hospital serving the Mogilev Oblast — a region with documented Chernobyl fallout exposure in its northern districts; Phase II–III in cardiovascular, oncology, and internal medicine; provides central-eastern Belarusian patient coverage for multi-site designs; increasingly active research portfolio as investigator training programs from BSMU extend into regional hospital networks across the country.
These are the primary regulatory, academic, and industry bodies shaping Belarus's clinical research ecosystem.
Belarus's primary regulatory authority for clinical trial oversight, pharmaceutical policy, and national healthcare strategy; oversees the RCETH pharmaceutical review body and the Republican Ethics Committee; operates within the EAEU Common Pharmaceutical Market framework; sponsors should engage their compliance functions to assess applicable sanctions implications for their specific programs prior to engagement.
The Ministry of Health's technical arm responsible for scientific evaluation of clinical trial applications, pharmaceutical dossier review, and GCP inspection of research sites in Belarus; applies EAEU unified pharmaceutical standards alongside national Belarusian regulations; the primary technical review body that international sponsors engage during CTA submission in the Belarusian market.
The supranational regulatory body governing the EAEU Common Pharmaceutical Market across Belarus, Russia, Kazakhstan, Armenia, and Kyrgyzstan; sets unified GCP, GMP, and clinical trial standards applicable in Belarus; EAEU-recognized clinical trial data from Belarusian sites can support regulatory submissions across the full EAEU member state market of approximately 183 million people.
Belarus's oldest, largest, and most prestigious medical university, founded in 1930 and the primary backbone of the national investigator pipeline; affiliated with Minsk's major clinical research hospitals and the national specialist research centres; drives GCP curriculum modernization and international academic exchange programs; the institution of origin for the majority of Belarus's senior research-active investigators across all major therapeutic areas.
Northern Belarus's dedicated medical university and a significant secondary source of GCP-trained investigators for the regional hospital network; VSMU faculty conduct active clinical research in cardiovascular disease and oncology in collaboration with the Minsk national centres; the primary academic driver of investigator training in northern and northwestern Belarus.
Western Belarus's dedicated medical university and the academic anchor for clinical research capacity in the Grodno and Brest regions; GrSMU conducts active research programs in cardiovascular medicine and oncology; the primary investigator training body for western Belarusian research sites and an important partner for sponsors seeking full national geographic coverage in multi-site Belarusian trial designs.
The research administration and scientific coordination arm of Belarus's flagship oncology institution; manages the Belarusian national cancer registry, coordinates investigator-initiated and commercial Phase I–IV oncology trial portfolios, and maintains active participation in CIS and international oncology research consortia; the primary scientific interface for international oncology sponsors evaluating Belarusian site capabilities.
Global CRO with CIS regional coverage historically including Belarus; Phase II–IV trial management across cardiovascular, oncology, and infectious disease indications; RCETH regulatory submission expertise and EAEU framework navigation; sponsors should confirm current operational status with IQVIA directly given the evolving CIS operational landscape since 2022.
International CRO with CIS regional coverage including Belarus for Phase II–IV oncology and cardiovascular programs; established investigator relationships across Minsk's national research centre network; sponsors should confirm current ICON Belarus operational status and applicable compliance considerations for their specific program prior to site activation.
CIS-specialist CRO with historical Belarusian site relationships across cardiovascular, oncology, and CNS indications; full regulatory submission, contracting, and patient recruitment management under the EAEU pharmaceutical framework; experienced in multi-country CIS trial designs combining Belarusian, Russian, and other CIS sites within a unified regulatory submission.
Global CRO with CIS regional operations including Belarus for Phase II–III trial management and EAEU regulatory strategy; cardiovascular and oncology therapeutic area depth across Minsk's national hospital network; sponsors should engage directly with Parexel to confirm current Belarus operational capacity and applicable compliance requirements before initiating site feasibility discussions.
Belarus remains a clinically capable research market with strong specialist institutions, particularly in oncology, cardiovascular care, infectious disease, and radiation medicine. Its research potential should be considered alongside current operational, regulatory, and compliance requirements, which may vary by sponsor, jurisdiction, and study design.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.